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ABSTRACT
This report summarises plans for radioisotope production at Lucas Heights
over the period 1966-71 and indicates how these are based on present trends of
demand for radioisotopes. The programme is discussed in terms of available
staff and facilities; while some small staff increases will be required, the
facilities presently being commissioned should be adequate over this-period.
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1. INTRODUCTION
Production of radioisotopes at the Research Establishment began in 1960
Originally the emphasis was on the production of radioisotopes -which required the
minimum of chemical or other processing. With the gradual improvement of
facilities it has been possible to increase the range of products. The
completion of the extensions to the Isotope Production Building will enable a
substantial increase in production of processed radioisotopes.
Long-term planning of radioisotope production has, during the initial period,
been restricted largely to the field of radiography and teletherapy sources.
The production of other radioisotope sources has necessarily been on a more ad hoc
basis pending the development of facilities and assessment of demand.
The stage has now been reached where it is both possible and desirable to
plan for the production of a much wider range of radioisotopes on a long-term
basis. This report considers the programme for a five-year period ending in
December 1971 and takes into account the experience of the first five years of
radioisotope production at Lucas Heights, It also takes into account the policy
as approved by the Commission,, which was stated as follows:;
"Radioisotopes may be produced at Lucas Heights in the following cases} where
special circumstances exist or where they can be produced economically -
(i) where the radioisotope has a short half life arid it is necessary to
produce it locally in order to satisfy domestic requirements, for example
sodium-24 and gold-198,
(ii) where importation is uneconomic, for example because of shielding, for
example iridium-192 and cobalt-60,
(iii) where production in Australia is necessary in order to ensure
continuity and convenience - primarily for medical purposes, These radioisotopes
would generally have short lives, for example iodine-131 arid phosphorus-32,
(iv) where there is reactor space and surplus reactivity available in the
reactor and the cost of irradiations would be trivial in. relation to the value
of the radioisotopes produced. Examples are cobalt-60 and iridium-192,
(v) activation analysis - producing radioisotopes in situ for particular
experiments, for example irradiation of copper in butter, manganese in ore,
activation of superphosphate, etc.
(vi) labelling compounds - preparation of a particular radioisotope for
- 2
 -
labelling purposes, for example labelling of silt with gold -198, where special
factors are involved such as short half life, or the need to irradiate a local
material, or cost".
It should be noted that where radioisotopes are produced within the policy
stated above, there is generally an- advantage to be gained by increasing the
scale of production provided that adequate markets can be found for the product
2. ASSUMPTIONS ON. WHICH THIS PROGRAMME, IS BASED
The proposed programme assumes the following:
(i) That during the next five years there will be an increased demand in
Australia and New Zealand for the most commonly used radioisotopes. Justific-
ation for this may be found in:
(a)
(b)
(c)
the increasing development and sophistication of Australasian
industry, research and medicine,
the world trend to advancing radioisotope technology, and
the growing importance of radioisotopes in medical diagnosis and
biological research. (The issue of supplementary regulations
to the Therapeutic Substances Act to specify radioactive
pharmaceutical preparations should lead to a marked increase in
demand for certain items which were hitherto impossible or
difficult to obtain) .
(ii) That the A. A. E.G. will be able to some extent to penetrate the already
existing radioisotope market in South East Asia.
(iii) That a well defined research and development effort by the Radioisotope
Production Section is focused on improving routine products, on developing new
processes, and, in general., maintaining a level of technical competence in step
with that of other radioisotope producers .
(iv) -That the present HIFAR irradiation facilities allocated to the Isotope
Division will be increased by at least two hollow fuel element positions for
fission spectrum neutron activation and possibly two 4V facilities (for bulk
cobalt-60 production) .
The future activities of the Isotope Production Section are considered under
the following heading-';;
(a) Production of large sealed sources of cobalt-60.
(b) Production of radioisotopes of short and medium half-life which require
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little post-irradiation treatment.
(c) Radiochemical and radiopharmaceutical preparations.
(d) Service irradiations. (Keutron activation and post-irradiation
handling of items supplied by customers),
(e) Other service work, (This includes loading operations of sources into
containers and apparatus; the disposal of replaced sources and the examination,
repackaging'and dispensing of radioisotopes which have been imported in bulk or
in units),
3. LARGE SEALED COBALT-60 SOURCES
It ia expected that the sale of large sealed cobalt-60 sources will continue
to provide a large proportion, of the revenue from radioisotope trading. The
emphasis will continue to be on the production of high specific activity material
and of teletherapy sources. It is, however, anticipated that during this period
a significant proportion of the cobalt-60 produced could be sold in the form of
unsealed bulk sources.
Market assessments have shown that, although the demand for teletherapy
sources was fairly constant in Australia, New Zealand, South East Asia, and India
in the past three years, a steady increase in demand can be expected up to 1971.
There has been an upward trend in other parts of the world, notably Japan,
recently and the predicted slump in demand for cobalt-60 due to accelerator-
developments, did not eventuate. It is expected that the Australian share in
world markets will increase as a result of active sales promotion now being
carried out.
The present annual production of cobalt-60 at Lucas Heights is approximately
30,000 curies of teletherapy cobalt-60 and about 10,000 curies of low specific
activity cobalt-60 for gamma radiation applications, It is proposed to increase
this production level over the next five years; improved activation techniques
will be used to increase the specific activity of teletherapy cobalt above the
present maximum of 250 curies per gram- The feasibility of increasing production
in HIFAR of high specific activity cobalt-60 has been examined. Additional
cobalt will be irradiated in hollow-fuel-element rigs and this should
approximately double the production of cobalt-60.
4. PRODUCTION OF RADIOISOTOPES OF SHORT OR. MEDIUM HALF-LIFE WHICH REQUIRE
LITTLE POST-IRRADIATION TREATMENT
The work involved with this type of radioisotope is only concerned with
_ A _
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target preparation and encapsulation (where necessary), irradiation, post-irradiation
measurement and preparation for despatch. Table 2 shows that during the financial
years 1964/65 and 1965/66 iridium-192 and ccbalt-60 (as level gauge and radiography
sources) and gold-198 and yttrium-90 (as medical implants) head the list of
unprocessed radioisotopes required. The Table also shows an increase in demand
for these products. Approximately sixty other unprocessed radioisotopes are
offered in the radioisotope catalogue, "but the demand for these is small. The
financial return in relation to the effort and resources required for production
is very good in the case of iridium-192 and cobalt-60 and it is expected that the
demand for these and the other unprocessed radioisotopes, in particular thulium-170
and gadolinium-153, will rise steadily during the next five years. A conservative
estimate would predict an increase in demand by a factor of 2 to 3, but very great
flexibility in production capacity is now available.
5. RADIOCHEMICAL AND RADIOPHARMACEUTICAL PREPARATIONS
Preparation of radiochemical and radiopharmaceutical products involves post-
irradiation chemical processing of various degrees of complexity. It is usually
necessary to produce the radioisotope in solution in the particular chemical form
required by the user, These radioisotopes are used extensively in scientific
research, industrial and field tracer experiments, and in medical diagnosis and
therapy. The latter applications frequently demand sterile, isotonic, pyrogen-
free products. In general the specification, for purity and radioactive content
is more strict for this type of product than that described in Section 4. .,
Table 2 shows jthe pattern of demand for chemically processed radioisotopes in
1964/65 and 1965/66 and Table 3 summarizes some of the principal requirements
for medical use.
The details for chemically processed radioisotopes during the financial year
1964/65, given in Table 2, refer only to materials for industrial scientific use.
Medical preparations were not on the A.AoE.C. production schedule during that
period. The demand for radiochemicals in the industrial and scientific fields
is sporadic and highly variable in the quantities required per shipment. For
this reason, there are insufficient statistics to predict the future pattern.
The previous pattern of demand for the more popular medical radioisotopes
obtainable from overseas is presented in Figure 2, These statistics are taken
from the annual report of the Commonwealth X-Ray arid Radium Laboratories in
Australia and also include the figures for New Zealand published by the National
Radiation Laboratory,
Because of legal restrictions, the commencement of production of
radiopharmaceutical solutions did not start in Australia until July 1965, Until
that date, the medical profession in Australia and New Zealand was virtually
without supplies of the short-lived hard gamma emitters, such as sodium-24,
potassium-42 and bromine-82, which are very popular overseas. Consequently, there
are no demand statistics to give a firm indication of a future requirement in
this field. However, it is known definitely that they would be used if
available. The long-term planning can therefore only be based on comparable
consumption statistics from other countries of similar development. For those
radioisotopes which have been used in previous years (Figure 2) it can fairly be
assumed that demand will increase by a factor of 2 to 3 in the next five years.
Some of the nearer centres in Asia are also within economic range for supply
of the shorter lived radioisotopes arid are expected to have some demand for
A.A.E.G. products,
In general terms, the radiochemical or radiopharmaceutical preparation
requires the greatest effort in skilled manpower in radioisotope production.
Therefore, standard stock solutions of a gi\ren activity are produced at regular
intervals in a shielded facility equipped with apparatus to deal with one or a
small number of chemical processes, The economic employment of staff made
possible in this method of production far outweighs the incidental waste of
radioactive material. All major radioisotope suppliers employ this technique
for standard products.
Table 4 and Figure 3 present a production scheme for radiochemicals, based
on predicted demands, which is possible with the design of the Radiochemical
Wing, Block A, Building 23 at Lucas Heights. This production scheme for
radiochemicals has been designed to be flexible enough to cope with credible
variations in quantity and frequency of the standard products listed. It is
also designed to accommodate production at irregular intervals of non-standard
isotopes such as fluorine-18, magnesium-28, iodine-125, iodine-132, molybdenum-99,
technetium-99m,and small amounts of fission products, and very large processed
sources for industrial and scientific applications.
The preparation of labelled compounds, which are becoming important in
scientific research, with a possible few exceptions, is outside the capacity of
both the proposed plant and staff complement. Mercury-197 labelled neohydrin
(half life 65 hours) is now in demand in Australia and is not satisfactorily
available from overseas. Production at Lucas Heights should be possible after
- 6 -
a short period of production development* Commonwealth X-Ray and Radium
Laboratory estimates an initial demand of approximately six shipments per week
totalling 10-20 mCi. The demand for compounds labelled with other very short-
lived radioisotopes is small at present, but demands may arise for medical uses,
6
• SERVICE IRRADIATIONS
There is small demand for radioactivation of materials supplied by clients
for various purposes such as activation analysis and industrial and scientific
tracer work., In general, this is very similar to the products described in
Section 4, with the client supplying the target material.. Any anticipated
demand in the future can be accommodated easily in present facilities,
7 . OTHER SERVICE WORK
The principal service in this category is the importing of non-medical
radioisotopes that for various reasons are best obtained from overseas. In
general., this includes radioisotopes which cannot be produced in HIFAR, and
labelled compounds of long-lived radioisotopes for which the small Australian
demand does not at present justify local production. (See Table 5). Apart from
the administrative aspects of procurement, all imported radioisotopes are
inspected for safety reasons and to ensure that the import meets the customers'
specification. A small part of the handling facilities available has been
allocated for this service,. Where sufficient demand exists it is anticipated
that some of the radioisotopes will be imported in bulk and dispensed at the
Research Establishment for distribution in small lots.
Other miscellaneous service work includes the loading of sources into
clients' equipment, special encapsulations to order and the disposal of replaced
or spent sources..
8.. FACILITIES
(a) Large Sources of Cobalt-60
The cobalt-60 handling cell and its necessary ancillaries are now in full-
scale operation and it is unlikely that any major additions or alterations will be
required over the next five years. The only facility demands for this aspect of
the programme will involve new irradiation rigs and a small increase in the number
of heavily shielded -:-ansport containers.
(b) Non-Processed Radioisotopes of Short and Medium Half-Life, Service
Irradiations ar.d Miscellaneous Service^
All facilities necessary to achieve the programme outlined in Sections 4, 6,
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and 7 are either in existence or in an advanced state of design and construction.
Figure 1 is a diagram of the materials flow when all these facilities are in
operation. It demonstrates that the shielded cells on the northern part of the
radioisotope handling bay in Building 23, presently used exclusively for the
manufacture of unprocessed radioisotopes, will also be required for the initial
post-irradiation handling of activated substances which will be chemically
processed in Building 23A. This requirement must be accounted for in the
assessment of the maximum activity allowable in the cells. In order to avoid
undue handling problems some increase in the present shielding of these
facilities must be incorporated in the building programme for the period under
review.
These facilities will cope with practically all the demands made by service
irradiations and the other miscellaneous service activities, including dispensing
of gaseous radioisotopes which have been imported in bulk.
(c) Radiochemical and Radiopharmaceutical Preparations
The radiochemical facilities in Building 23A will be capable of handling the
programme envisaged for the next five years. Figure 3 relates shielded
facilities in this laboratory and staff effort to this programme.
9. RESEARCH AND DEVELOPMENT
A definite proportion of staff effort, materials, and facilities of the
Radioisotopes Production Section Is set aside to improve the •>quality of present
products and processes and develop new products for which demands arise and which
can be made using local resources„
A general programme of research and development has been drafted and is now
operational. In the development of new products the programme favours, in
principle, the short-lived radioisotopes. It is divided into the following
categoriesJ
(I) Chemistry
Projects in this field are directed towards the development of techniques to
produce radiochemical compounds and control certain quality aspects on a routine
basis. Rapid and reliable chemical separation methods with the object of
producing carrier free radiochemicals, which are the product of other than (n,r)
activation reactions or daughter products, are a highlight in this research.
(ii) Physics
The physics research programme Is devised to develop suitable activity
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measurement techniques for the determination of the radioactive strength and
radioisotopic purity of products. It also is concerned with a fuller
understanding of activation processes and mechanisms in reactors or other activity
inducing devices.
(iii) Engineering arid Metallurgy
The effort in this field is directed towards the development of more
efficient activation techniques in HIFAR, improvement of transport and handling-
container designs for radioactive materials, safe and efficient encapsulation
methods for radiation sources, (in particular those with low penetrating power),
and shaping of metallic radiation sources, notably cobalt-60.
10. STAFF
The present staff allocation is shown in Table 1. It is difficult to make
an accurate prediction of the staffing requirements for the Section over as long
a period as five years. This is primarily because staff requirements are
affected by the demand for various local radioisotope products, During the last
year this demand rose sharply. If, as expected, the demand continues to increase
steadily, further staff would be required to maintain the required production.
Over the five year period under consideration, approximately five more staff
would be needed, mainly to assist in the production of processed, short-lived
radioisotopes,
11. CONCLUSION
This report gives a summary of the current plans for radioisotope production
at Lucas Heights. These plans have been evolved to meet a situation in which the
overall demand for locally produced radioisotopes is confidently expected to
increase by a factor of, on average, at least two or three, Predictions in
relation to specific radioisotopes are less certain, complicating factors being
changes in medical practice (this affects primarily processed radioisotopes) and
the general stimulation of demand which has resulted from the more ready
availability of the local products., Overseas sales are difficult to forecast;
however, a steady increase in exports is expected, particularly to New Zealand.
TABLE 2
SHIPMENTS OF RADIOISOTOPES IN SIGNIFICANT DEMAND PRODUCED, BY THE RADIOISOTOPES
PRODUCTION SECTION FROM JULY 1964 TO JUNE 1966 (EXCLUDING COBALT-60 TELETHERAPY
AND LARGE GAMMA RADIATION SOURCES)
RADIOISOTOPE
Ir-192
Co-60
Tm-170
Au-198
Y-90
Cr-5i
P-32
Na-24
K-42
Br-82
Gd-153
Rb-86
Ca-45
Service
Irradiations
TOTAL
UNPROCESSED
Activity (mCi)
1964/65
748,600
12,300
3,100
700
0.5
-
2,700
40
-
-
-
-
1965/66
1,161,940
21,283
2,131
2,270
1,159
-
-
-
-
22
-
-
No. of Units
Consigned
1964/65
59
40
47"
42"
1
-
14
2
-
-
-
-
279
491
1965/66
103
483
5
0603
0267
-
-
-
-
2
-
-
139
1503
PROCESSED
Activity (mCi)
1964/65
-
-
36,100
*306,200
-
800
120
-
-
20
8
1965/66
-
-
8,505
102 ,000+
2,436
1,687
825
41
-
108
44
No, of Units
Consigned
1964/65
-
-
8
19
-
8
6
-
-
4
4
49
1965/66
-
-
17
65
197
45
10
51
-
10
19
414
Refers to shipments
Refers to units. Unit system adopted with introduction
of computer data storage, For example a shipment of
Au-198 may contain up to 15 units - a shipment of Y-90
up to 5 or 6.
Substantial proportion used by AoAoEoC. in hydrological
studies.
TABLE 5
THE APPLICATION OF ARTIFICIAL RADIOISOTOPES IN MEDICINE AND BIOLOGY
Application, or Suggested
Application, in Medicine
Therapy: whole body irrad-
iation , erythropoeisis,
polyglobuly.
Diagnosis: circulation
measurements 'with Na-24
labelled plasma, Determination
of the extravascular space
according to the dilution
method. Blood circulation in
extremities and organs. Cardiac
insufficiencv.
Therapy: surface therapy of
deformities and malformations,,
skin lesions, eczema. Chronic
leukaemia and polycythaemia.
Selective irradiation - with
colloids containing P-32.
Diagnosis: blood volume deter-
minations and circulation
diagnosis with P-32 labelled
erjrthrocytes.
Therapys experiments with
selective irradiation of the
joints,
Diagnosis: recent investigations
regarding sulphur accumulation
in tumours,
Diagnosis: blood volume and
circulation studies with Cr-51
labelled erythrocytes.
Therapy: local irradiation of
lymph nodes. Distribution of
colloidal Mn02 in the
reticuloendothelial system.
Isotope
Fluorine
F-18
Sodium
Na-24
Phosphorus
P-32
Sulphur
S-35
Chlorine
Cl-36
Cl-38
Potassium
K-42
Calcium
Ca-45
Ca-47
Chromium
Cr-51
Manganese
Mn-52
Mri-54
Application in Biological
and Physiological Research
Physiology and chemistry of
bones and teeth.
(Also Na-22) Excretion resorp-
tion; permeability of cap-
illaries, gastric mucosa, in-
testinal walls, placenta, or-
ganic cell walls. Distribution
between plasma and tissue.. Ion
transport,
Mineral metabolism, intermed-
iary metabolism.
Permeability studies. Inter-
mediary metabolism. Metabolism
of sulphur-containing amino-
acids and peptides„ S-35
labelled Pharmaceuticals.
Mineral metabolism.
Mineral metabolism, permeabil-
ity, ion transport through
membranes.
Mineral metabolism, adrenal
physiology,
Mineral metabolism, incorpora-
tion of Ca in the bones of
rachitic and vitamin-D treated
animals. Bone healing.
Plasma -albumin investigations
with 51CrCl3.
Mineral metabolism.
Continued
TABLE 3 (Continued)
Application., or Suggested
Application,, in Medicine
Diagnosis0, blood volume;
of erythrocytes
Therapy: teleeurie therapy
external (high depth do-^ea) .
Co-wire for local application,
Intracaviltary cobalt chloride
solution in rubber bags as
cavity applicator (bladder).
Therapyv intratumoral therapy.
Zn-63 as insoluble sulphide and
as sol. intraperitoneal and.
intrapieural application.
Zr--63 in coarse-disperse
sulphide form results in sel-
ective fixation in the lungs.
Diagnosis-: minute-volume
determination
Therapy:- therapy of bone
sarcoma;
Therapy' selective irradiation
of the thyroid, Treatment of
hyperthyroidism, thyroid
earcinc\;iu , diffuse and nodular
struma,.
Diagnosis: thyroidal dysfunction,
Localization, of tumours by
means of 1-131 diiodofluorescin.
isotope
Iron
:-e-55
Fe-59
Cobalt
Co-60
Zinc
Zn-63
Zn-65
Broimne
Br-82
Krypton
Xr-85
Strontium
Sr-89
Iodine
1-131
Therapy (i) in insoluble form
(pectin sol) for intra-cavity
treatment. Peritoneal and
pleurocarcincsis, Tntra-
tumoral tiierapy „
Therapy (ii) as pi-stallic gold
seeds for tumour implantation.
Diagnosis: as a lab',.lied diuretic
Neohydrin-Eg-197 in tne scanning
of brain tumours,
Diagnosis; in various chemical
formt-: for the vlsu3.lisa.ticn and
study of several organs,
Gold
Au-198
Mercurv
Hg-197
Technstium
Tc-99m
Application in Biological
and Physiological Research
Mineral metabolism, blood
physiology, resorption by gas-
tric and intestinal mucosa.
Distribution of Fe in the or-
ganism. Blood preservation..
Mineral metabolism.
Mineral metabolism. Lifetime of
leucocytes.
Hilectrolyte exchange. Thyroid
physiology, distribution of
brominated dyes.
Respiratory gas exchange.
Absorption-distribution-
excretion o Bone physiology
Iodine metabolism, Thyroid
physiology.
Absorpt iori-distribut ion-
excretion; distribution in
arthritis.,
Continued.
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TABLE 3 (Continued)
Application, or Suggested
Application, in Medicine
Therapy (i) as colloidal yttrium
silicate - alternative agent to
colloidal gold.
Therapy (ii) as ceramic yttria rods
for pituitary gland ablation.
Isotope
Yttrium
Y-90
Magnesium
Mg28
Application in Biological
and Physiological Research
Mineral metabolism.
•\
\
TABLE 4
STANDARD RADIOCHEMICAL PRODUCTS TO BE PRODUCED AT LUCAS HEIGHTS BETWEEN 1966 AND 1971
Radioisotope
Potassium-42
Sodium-24
Bromine-82
Iodine-131
Phosphorus-32
Chromium-51
Half
Life
12,5 hr,
15 hr.
36 hr.
8 d
14 d
27.8 d
Production
Process
4.1
•K(n,T)4 aK
23Na(n,r) Na
13
°Te(n?T)131Te
131<i'
32r./
50,
'Cr(n,r)5lCr
Anticipated Regular
Batch Size for Stock;
Frequency.
Probable Chemical
Forms (other de-
mands may arise)
50 mCi/week Isotonic chloride solution
100 mCi/week (i) Solid carbonate
(ii) Isotonic chloride
solution
100 mCi/week NH4 3 Na or K bromides3
isotonic solri, if required
1000 mCi/week (i) Iodide in NaOH
(ii) Iodide in NasS203
(iii)Iodide in isotonic
buffer
1 C i/month (i) 1-04 in dilute HC1
(ii) P04 in isotonic
buffer
100 mCi/month (i) Aqueous chromic
chloride
(ii) Isotonic chromic
chloride
(iii)Isotonic potassium
chrornate
Field of Expected Usage
Medical
(i) Industrial
(ii) Medical
Industrial and medical
(i) Protein labelling
(ii) Medical-oral admin-
istration .
(iii)Medical-parenteral
administration
(i) Scientific, indust'l
and medical research
(ii) Medical-parenteral
administration
(i) Industrial
(ii) Medical-general
protein labelling
(iii)Medical-red blood
cell labelling
Continued.
i*
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TABLE 4 (Continued)
Radioisotope
Copper -64
Yttrium-90
Gold-198
Technetium-99m
Magnesium-28
Mercury-197
Calcium-47
Fluorine -18
Half
Life
12.8 hr.
64.5 hr.
2.7 d
6.0 hr.
21.3 hr.
67 hr.
4.7 d.
1.7 hr.
Production
Process
63Cu(n/T)64Cu
89Y(n,r)9°Y
197Au(n,r)198Au
98Mo(n,T)99Mo p Tc™
^
6Mg(t,p)28Mg
196Hg(n5T)l97Hg
soTi(n,Q:)4TCa
160(t,n)18F
Anticipated Regular
Batch Size for Stock;
Frequency
100 mCi/week •
100 mCi/week
100 mCi/week
2 Ci/week
20 mC i/month
50 mCi/week
10 mC i/month
20 mC i/month
Probable Chemical
Forms (other de-
mands may arise)
(i) Aqueous chloride 3oln.
(ii) Isotonic EDTA complex
(i) YCLa aqueous solution
(ii) Yttrium silicate
colloid
(i) Aqueous auric
chloride
(ii) Gold colloid
(i) Pertechnetate
generator
(ii) Colloidal
heptasulphide
(iii)Labelled albumin
Isotonic chloride solution
Labelled neohydrin isotonic
solution
Isotonic chloride solution
Isotonic sodium fluoride
solution
I
Field of Expected Usage
(i) Industrial and
Scientific Research
(ii) Medical
(i) Industrial
(ii) Medical
(i) Industrial
(ii) Medical
Medical
Medical
Medical
Medical
Medical
TABLE 5
RADIOISOTOPES FOR WHICH PRODUCTION BY A.A,E.G. IS AT
PRESENT NOT POSSIBLE OR DESIRABLE AND WHICH
WILL NORMALLY BE IMPORTED
Radioisotope Preparation
Accelerator produced neutron
deficient isotopes
2. Fission products
3. Tritium and other radioactive
gases
4. Tritiated water
Labelled compounds of carbon-14,
tritium-3, sulphur-35, selenium-75,
chlorine-36 and iodine-1'31
Special sources (e,g. tritium-3
targets, Mossbauer)
Processed radioisotopes not
produced by A.A.E.G.
Reason Not Produced by
Australian accelerator resources
are very limited»
Expensive and complex plant
required, but may be justified in
some instances, e.g. Tc99m ,
Supply assured from overseas - no
transport problems.
as 3 above.
Extensive resources and highly
trained staff required, and not
normally economic .
Very small Australian demand
Many processed radioisotopes will
be imported, especially those of
long half-life.
4000
3000
(a)2000
- mCi P-32
C.X.R.L.
1000
61 62 63 64 65 66
(W
500
250
0
T 1
mCi Cr-51
CX.R.L
1
D.X.R.L.
6! 62 63 64 65 66
10,000
D.X.R.L.
61 62 63 64 65 66
"I T
1000 -
(d)
500 -
61 62 63 64 65 66
« 1 T 1
mCi S-35
61 62 63 64 65 66
4000-
2000-
61 62 63 64 65 66
61 62 63 64 65 66
FIGURES PUBLISHED BY:
C.X.R.L.- COMMONWEALTH X-RAY
AND RADIUM LABORATORY
D.X R.L. - NATIONAL LABORATORY. N.Z.
(DOMINION X-RAY AND
RADIUM LABORATORY.)
FIGURES ARE FOR MEDICAL TREATMENT
AND MEDICAL RESEARCH ONLY.
FSGURE 2. AUSTRALASIAN USAGE OF MEDICAL
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